VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sailor who wrote (2908)	12/1/1997 10:38:00 AM
From: g.w. barnard	Read Replies (1) of 23519

sailor, is this what you are talking about?? gw GREAT NECK, N.Y., Dec. 1 /PRNewswire/ -- Robert M. Cohen & Co. analyst Keith R. Bossey upgraded his rating on Vivus, Inc. (NASDAQ:VVUS) to a buy from speculative buy and maintained his six-month price target of $50.50 per share. The upgrade was based on Vivus' announcement that it gained regulatory approval to market its Muse impotence treatment in the United Kingdom. SOURCE Robert M. Cohen & Co.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next